Eurobact II will investigate the mortality and morbidity of hospital-acquired blood stream infections in patients treated in intensive care units (ICU). It will investigate the effects of the micro-organism and its characteristics, such as type and resistance to antibiotics on the infection and its consequences. It will also investigate the effects of the antibiotics and other treatments on survival of patients. Eurobact II will include patients from multiple ICUs in multiple countries.
Eurobact II is a multinational multicentre cohort study that will include patients with hospital-acquired blood stream infections (HA-BSI) treated in ICUs around the globe. It will provide with an update of the epidemiology of HA-BSI since the Eurobact I study. It is designed to investigate the effects of HA-BSI on mortality at day 28. To describe the determinants of outcomes of HA-BSI, specifically the effects of the source of infection, the microorganism, the characteristics of antimicrobial therapy and of source control. It will investigate patient specific and organizational factors and will describe the determinants of management of HA-BSI in ICUs.
Study Type
OBSERVATIONAL
Enrollment
3,058
Redcliffe Hospital
Brisbane, Queensland, Australia
Reanimation Medicale et Infectieuse-Hopital Bichat
Paris, France
Mortality
Vital status
Time frame: 28 days
Progress of organ failures
Assessed by the components of the SOFA score
Time frame: 7 days
Days free or organ supportive therapy
Days free of renal replacement therapy, mechanical ventilation, vasopressors, intensive care unit
Time frame: 28 days
Clinical cure
As evaluated by the treating clinician
Time frame: 7 days, 28 days
Microbiological cure
Presence of persisting or relapsing blood stream infection
Time frame: 7 days, 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.